This randomized study is about 100 patients with hip fracture that were treated with hemiarthroplasty in 4 groups of 25. Group A includes patients who were given :
- recombined human erythropoetin (r-HuEPO) 40.000 I.U. sc the day −1, +1, +3, +7 (day 0 = day of surgery). - sulfate iron per os from the day −1 till +15 - blood from the autotranfusion apparatus (it is the patient’s blood that is collected in the autotransfusion apparatus the 5 first postoperative hours). Group B includes patients who were given :
- sulfate iron per os from the day −1 till +15 - blood from the autotranfusion apparatus Group C includes patients who were given :
- recombined human erythropoetin (r-HuEPO) 40.000 I.U. sc the day −1, +1, +3, +7 (day 0 = day of surgery). - sulfate iron per os from the day −1 till +15 Group D is the control group (that was not given none of the above therapies). We study and present the first results of the effect of the recombined erythropoetin, the sulfate iron per os and the patient’s blood from the autotransfusion apparatus to patients with hip fracture who were treated with hemiarthroplasty in concern to the transfused blood units for the restoration of the hematocrit to a tolerable level.
